Hydroxyzine Pamoate

CHEMBL1200467 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
763.3 g/mol
LogP
Phase
4

This pamoate salt form of hydroxyzine is used in capsule form for anxiety and tension relief, as well as allergic conditions. The pamoate salt allows for a slightly different absorption profile compared to the hydrochloride salt. Like other hydroxyzine formulations, it carries anticholinergic side effects including dry mouth and drowsiness.

分子量

763.3000 g/mol

TPSA

151.00 Ų

治疗领域

作用机制

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1

InChI

InChI=1S/C23H16O6.C21H27ClN2O2/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-10,24-25H,11H2,(H,26,27)(H,28,29);1-9,21,25H,10-17H2

Molecular Formula

C44H43ClN2O8

HBD / HBA

5 / 10

可旋转键数

12

重原子数

55

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This pamoate salt form of hydroxyzine is used in capsule form for anxiety and tension relief, as well as allergic conditions. The pamoate salt allows for a slightly different absorption profile compared to the hydrochloride salt. Like other hydroxyzine formulations, it carries anticholinergic side effects including dry mouth and drowsiness.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Hydroxyzine Pamoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200467. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 25096. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.